Objective: To determine arterial hypertension prevalence, knowledge, treatment, and control, in Peru. Design, setting, participants: Cross sectional survey application and blood pressure measurement performed in 26 cities in 18 year-old or over adult population, 10 cities in the coast, 12 in the mountains at different altitude (below and above 3 000 meters above sea level), and 4 in the jungle. Interventions: The study done between February and November 2004 considered valid 14 256 surveys. Blood pressure was obtained with the same standard equipment, and diagnosis followed the recommendations of the Joint National Committee’s Seventh Report. Results: Arterial hypertension prevalence was 23,7% (males, 13,4%; females, 10,3%). In the coast, the prevalence was 27,3%; in the mountains, 18,8% below 3 000 meters and 22,1% above 3 000 meters; in the jungle, 22,7%. After the fourth decade of li...

Objective: To determine arterial hypertension prevalence, knowledge, treatment, and control, in Peru. Design, setting, participants: Cross sectional survey application and blood pressure measurement performed in 26 cities in 18 year-old or over adult population, 10 cities in the coast, 12 in the mountains at different altitude (below and above 3 000 meters above sea level), and 4 in the jungle. Interventions: The study done between February and November 2004 considered valid 14 256 surveys. Blood pressure was obtained with the same standard equipment, and diagnosis followed the recommendations of the Joint National Committee’s Seventh Report. Results: Arterial hypertension prevalence was 23,7% (males, 13,4%; females, 10,3%). In the coast, the prevalence was 27,3%; in the mountains, 18,8% below 3 000 meters and 22,1% above 3 000 meters; in the jungle, 22,7%. After the fourth decade of li...

Isradipine, a new and potent antihypertensive dihydropyridine calcium antagonist, was evaluated in 132 patients (66.7% females and 33.3% males) withe the clinical diagnosis of mild to moderate hypertension, in an open multicenter study that took place in the hypertension, in an open multicenter study that took place in the hypertension clinics of several peruvian hospitals. The protocol include a wash out or diagnosis confirmation period of two weeks followed by 12 weeks of treatment with 2.5 mg isradipine twice daily.  The patients mean age was 56.7 (+-6.3), weight 66.9 kg (+- 11.0) and height 160 (+- 9.0). 30.3% of the patients had associated diseases, 86.4% had been previously treated for hypertension and 85.8% had a clinical diagnosis of arterial hypertension for more than one year.  After 90 days of treatment there was a mean decrease of 28.8 mmHg in the diastolic arterial...

Isradipine, a new and potent antihypertensive dihydropyridine calcium antagonist, was evaluated in 132 patients (66.7% females and 33.3% males) withe the clinical diagnosis of mild to moderate hypertension, in an open multicenter study that took place in the hypertension, in an open multicenter study that took place in the hypertension clinics of several peruvian hospitals. The protocol include a wash out or diagnosis confirmation period of two weeks followed by 12 weeks of treatment with 2.5 mg isradipine twice daily.  The patients mean age was 56.7 (+-6.3), weight 66.9 kg (+- 11.0) and height 160 (+- 9.0). 30.3% of the patients had associated diseases, 86.4% had been previously treated for hypertension and 85.8% had a clinical diagnosis of arterial hypertension for more than one year.  After 90 days of treatment there was a mean decrease of 28.8 mmHg in the diastolic arterial...